Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LLT-M1
- Development stage
- Preclinical
- Lead developer
- MediPrint Ophthalmics
- Modality
- Hydrogel Systems → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
LLT-M1 is a preclinical-stage medicated contact lens being developed by MediPrint Ophthalmics (formerly Leo Lens Technology) for the treatment of myopia. The product utilizes the company's proprietary 3D printing technology to incorporate a therapeutic agent into a contact lens, enabling the sustained and controlled release of the drug directly to the ocular surface. This delivery modality is designed to address the limitations of traditional eye drops, such as poor patient compliance and systemic absorption, by providing a more consistent therapeutic effect and improving ease of use, particularly for pediatric patients who are the primary target for myopia progression control.
02
Targets
PTGFR (Prostaglandin F2 alpha receptor)
Beyond the preview
Go deeper on LLT-M1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LLT-M1.